Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.

What was studied

This review compared drugs for a nerve disease called CIDP. It used a network meta-analysis. FcRn blockers were set against older immune care. Searches ran to February 2026. Only randomized trials were used. The main outcome was clinical response. Others were serious events, stops due to them and grip strength. Drugs were ranked using P-scores.

What they found

The analysis had 2,184 patients. Plasma exchange and steroids had the top odds of a clinical response. One FcRn blocker showed a clear response. It ranked top for grip strength change. Serious events on FcRn blockers were like placebo. Another ranked top for acceptability. Variation across trials was low to modest.

What it means for patients

The authors say plasma exchange and steroids had the strongest short-term effects. One FcRn blocker had a clear effect and top grip rank. IVIg remains a broadly supported comparator. The findings should inform, not replace, care choices made for each patient.

Why it is not certain yet

Grip strength is a distal motor outcome only. It is not a full measure of function. The team did not check effect changes at patient level. Marker status and past response were not checked. Long-term nerve results were not checked.

Source

Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.